Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
65 巻, 11 号
選択された号の論文の29件中1~29を表示しています
EDITORIAL
ORIGINAL ARTICLES
  • Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Tomotake Shirono, Ets ...
    2026 年65 巻11 号 p. 1450-1457
    発行日: 2026/06/01
    公開日: 2026/06/01
    [早期公開] 公開日: 2025/10/16
    ジャーナル オープンアクセス
    電子付録

    Objective Hepatic encephalopathy (HE) is a serious adverse event associated with lenvatinib (LEN) that requires discontinuation of the medication. We investigated the risk factors for HE in patients with hepatocellular carcinoma (HCC) who received LEN. We also explored the usefulness of rifaximin in preventing HE and LEN.

    Methods We enrolled 216 patients with HCC who had undergone LEN. The incidence of HE was evaluated [observational period 171 (1-2,079) days]. LEN dosage was assessed using the relative dose intensity (RDI). A decision-tree algorithm was constructed to reveal the profiles associated with HE.

    Results The incidence rate of HE was 8.8%. There were no significant differences in the age, sex, body mass index, or tumor stage between the HE and non-HE groups. A splenorenal shunt (≥8 mm in diameter) was identified as an independent risk factor for HE (hazard ratio 7.653, 95% confidence interval 2.489-23.535, p<0.001). A decision-tree analysis revealed that, in patients with splenorenal shunt and ALBI grade 2, HE occurred in 66.6% of patients with no refaxmin. In contrast, 16.6% developed HE in patients treated with rifaximin. Furthermore, the prevalence of RDI >70% was 20.0% and 66.7% in patients who did not receive rifaximin and rifaximin, respectively.

    Conclusion Splenorenal shunt placement is an independent risk factor for HE in patients with HCC receiving LEN. Furthermore, rifaximin prevented HE and contributed to a sufficient dose of LEN in patients with HCC, splenorenal shunts, and ALBI grade 2. Thus, rifaximin may be beneficial for the management of patients with HCC receiving LEN, especially those with HCC with splenorenal shunt and hepatic dysfunction.

  • Shuhei Nakanishi, Masashi Shimoda, Tomohiko Kimura, Junpei Sanada, Yos ...
    2026 年65 巻11 号 p. 1458-1463
    発行日: 2026/06/01
    公開日: 2026/06/01
    [早期公開] 公開日: 2025/10/23
    ジャーナル オープンアクセス

    Objective This study investigated the association between the phase angle (PhA), a marker of cellular health and body composition quality, and hemoglobin A1c (HbA1c), an indicator of glycemic control, in non-elderly (<65 years old) patients with type 2 diabetes mellitus (T2DM).

    Methods This cross-sectional study included 167 non-elderly T2DM patients. The participants were categorized into tertiles (low, middle, and high) based on their PhA values. A multiple logistic regression analysis was performed to examine the association between PhA tertiles and controlled HbA1c levels (defined as <7.0%) after adjusting for potential confounders, such as the age, sex, body mass index, waist circumference, and number of anti-diabetic medications used by the study participants.

    Results HbA1c levels were significantly lower in the middle (8.41%±2.06%) and high (8.35%±1.77%) PhA tertiles than in the low tertile (9.58%±2.86%). After adjusting for confounders, the odds ratios for achievement of controlled HbA1c in the middle and high PhA tertiles, compared with the low tertile, were 2.338 (95% confidence interval 1.006-5.432) and 2.666 (1.071-6.636), respectively. Furthermore, when analyzed as a continuous variable, PhA remained a significant and independent predictor of controlled HbA1c level.

    Conclusion PhA appears to be a useful independent indicator of glycemic control in non-elderly patients with T2DM. This non-invasive marker could contribute to the development of personalized therapeutic strategies that consider the cellular health and muscle quality.

CASE REPORTS
PICTURES IN CLINICAL MEDICINE
LETTERS TO THE EDITOR
feedback
Top